The National Comprehensive Cancer Network guidelines recommend testing for ALK rearrangement and ROS1 fusion for individuals with metastatic NSCLC since ALK inhibitors are recommended for the treatment of metastatic NSCLC in the first and second lines settings. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.